[go: up one dir, main page]

CY1119537T1 - Ρυθμιστες υποδοχεα cxcr 7 - Google Patents

Ρυθμιστες υποδοχεα cxcr 7

Info

Publication number
CY1119537T1
CY1119537T1 CY20171101149T CY171101149T CY1119537T1 CY 1119537 T1 CY1119537 T1 CY 1119537T1 CY 20171101149 T CY20171101149 T CY 20171101149T CY 171101149 T CY171101149 T CY 171101149T CY 1119537 T1 CY1119537 T1 CY 1119537T1
Authority
CY
Cyprus
Prior art keywords
cxcr
regulators
receiver
formula
pharmaceuticals
Prior art date
Application number
CY20171101149T
Other languages
English (en)
Inventor
Heinz Fretz
Philippe Guerry
Thierry Kimmerlin
Francois LEHEMBRE
Julien Pothier
Hervé VALDENAIRE Anja SIENDT
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CY1119537T1 publication Critical patent/CY1119537T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με παράγωγα του Χημικού τύπου (I) όπου τα (R1)n, R2a, R2b, R3a, R3b, R4, L1, L2, Χ, Υ και Ar1 είναι όπως περιγράφονται στην περιγραφή, με την παρασκευή τους, με φαρμακευτικά αποδεκτά άλατα αυτών, και με τη χρήση τους ως φαρμακευτικές ουσίες, με φαρμακευτικές συνθέσεις που περιέχουν μια ή περισσότερες ενώσεις του χημικού τύπου (I), και ιδίως με τη χρήση τους ως ρυθμιστές του υποδοχέα CXCR7.
CY20171101149T 2013-05-30 2017-11-02 Ρυθμιστες υποδοχεα cxcr 7 CY1119537T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2013054478 2013-05-30
PCT/IB2014/061774 WO2014191929A1 (en) 2013-05-30 2014-05-28 Cxcr7 receptor modulators

Publications (1)

Publication Number Publication Date
CY1119537T1 true CY1119537T1 (el) 2018-03-07

Family

ID=50943357

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101149T CY1119537T1 (el) 2013-05-30 2017-11-02 Ρυθμιστες υποδοχεα cxcr 7

Country Status (30)

Country Link
US (1) US9920010B2 (el)
EP (1) EP3004082B1 (el)
JP (1) JP6393749B2 (el)
KR (1) KR102302580B1 (el)
CN (1) CN105263924B (el)
AR (1) AR096490A1 (el)
AU (1) AU2014272718B2 (el)
BR (1) BR112015030095B1 (el)
CA (1) CA2912133C (el)
CL (1) CL2015003470A1 (el)
CY (1) CY1119537T1 (el)
DK (1) DK3004082T3 (el)
EA (1) EA028604B1 (el)
ES (1) ES2645470T3 (el)
HR (1) HRP20171597T1 (el)
HU (1) HUE036649T2 (el)
IL (1) IL242782B (el)
LT (1) LT3004082T (el)
MA (1) MA38679B1 (el)
MX (1) MX364104B (el)
MY (1) MY173564A (el)
NO (1) NO3004082T3 (el)
PH (1) PH12015502632A1 (el)
PL (1) PL3004082T3 (el)
PT (1) PT3004082T (el)
SG (1) SG11201509057UA (el)
SI (1) SI3004082T1 (el)
TW (1) TWI640510B (el)
UA (1) UA118562C2 (el)
WO (1) WO2014191929A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
CA2963447A1 (en) 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Cxcr7 receptor modulators
US20170112831A1 (en) * 2015-10-23 2017-04-27 James MERRITT Use of ccr1 antagonists as a treatment for tumors of the central nervous system
SI3798217T1 (sl) * 2016-07-28 2023-05-31 Idorsia Pharmaceuticals Ltd Piperidinski modulatorji cxcr7 receptorja
PE20191811A1 (es) 2017-05-18 2019-12-26 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
PE20191814A1 (es) 2017-05-18 2019-12-27 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
RS65594B1 (sr) 2018-01-26 2024-06-28 Idorsia Pharmaceuticals Ltd Kristalni oblici antagonista cxcr7 receptora (1-pirimidin-2-il-ciklopropil)-amida (3s,4s)-1-ciklopropilmetil-4-{[5-(2,4-difluoro-fenil)-izoksazol-3-karbonil]-amino}-piperidin-3-karboksilne kiseline

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896170A (en) 1969-02-26 1975-07-22 American Home Prod Intermediates for the preparation of 1,3-dihydro-2h-1, -benzodiazepin-2-ones
IL137720A0 (en) 1998-02-18 2001-10-31 Neurosearch As Compounds and their use as positive ampa receptor modulators
GB9816984D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
JP2004515494A (ja) 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ 治療剤
DE60327106D1 (de) * 2002-12-20 2009-05-20 Chemocentryx Inc Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
DK1954274T3 (da) * 2005-11-10 2011-01-31 Chemocentryx Inc Substituerede quinoloner og fremgangsmåder til anvendelse
WO2009076404A1 (en) 2007-12-10 2009-06-18 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
CA2963447A1 (en) 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Cxcr7 receptor modulators

Also Published As

Publication number Publication date
SG11201509057UA (en) 2015-12-30
AU2014272718B2 (en) 2018-06-28
US20160107997A1 (en) 2016-04-21
US9920010B2 (en) 2018-03-20
DK3004082T3 (en) 2017-10-02
IL242782B (en) 2019-06-30
HRP20171597T1 (hr) 2017-12-01
TW201529557A (zh) 2015-08-01
HK1223353A1 (en) 2017-07-28
MX364104B (es) 2019-04-12
WO2014191929A1 (en) 2014-12-04
PH12015502632B1 (en) 2016-03-07
MY173564A (en) 2020-02-04
ES2645470T3 (es) 2017-12-05
IL242782A0 (en) 2016-02-01
AU2014272718A1 (en) 2016-01-21
CA2912133A1 (en) 2014-12-04
MA38679A1 (fr) 2018-07-31
AR096490A1 (es) 2016-01-13
KR20160013197A (ko) 2016-02-03
NO3004082T3 (el) 2017-12-30
EA028604B1 (ru) 2017-12-29
TWI640510B (zh) 2018-11-11
CN105263924B (zh) 2018-10-19
EA201501163A1 (ru) 2016-06-30
EP3004082A1 (en) 2016-04-13
BR112015030095B1 (pt) 2023-02-28
CA2912133C (en) 2021-06-22
JP2016520120A (ja) 2016-07-11
PL3004082T3 (pl) 2018-01-31
CL2015003470A1 (es) 2016-06-17
EP3004082B1 (en) 2017-08-02
MX2015016429A (es) 2016-03-01
NZ715530A (en) 2020-12-18
KR102302580B1 (ko) 2021-09-15
CN105263924A (zh) 2016-01-20
LT3004082T (lt) 2017-10-25
MA38679B1 (fr) 2019-12-31
JP6393749B2 (ja) 2018-09-19
SI3004082T1 (sl) 2017-11-30
PH12015502632A1 (en) 2016-03-07
PT3004082T (pt) 2017-11-13
HUE036649T2 (hu) 2018-07-30
UA118562C2 (uk) 2019-02-11
BR112015030095A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
CY1119537T1 (el) Ρυθμιστες υποδοχεα cxcr 7
CY1125016T1 (el) Διαμορφωτες υποδοχεα πιπεριδινης cxcr7
CY1118735T1 (el) Παραγωγα βενζιμιδαζολο-προλινης
CY1121867T1 (el) Αναστολεις jak2 και alk2 και μεθοδοι για τη χρηση τους
NI201700096A (es) Derivados de 4h-pirrol[3, 2-c]piridin-4-ona
CY1119953T1 (el) Yποκατεστημενες πυριδοπυραζινες ως προτυποι syk ανοστολεις
CY1119387T1 (el) Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
JO3674B1 (ar) مشتقات ثنائية الحلقة جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
CY1117638T1 (el) Παραγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδιου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιναμιδιου ως ανταγωνιστες του υποδοχεα της ορεξινης
CY1121137T1 (el) Φαρμακευτικα σκευασματα που περιλαμβανουν ανταγωνιστες ccr3
MX373716B (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
CY1121361T1 (el) Παραγωγα υδροξυαλκυλ πιπεραζινης ως ρυθμιστες υποδοχεα cxcr3
CY1120008T1 (el) Βενζαμιδια
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
CY1116004T1 (el) Παραγωγα οξαζολυλ-μεθυλαιθερα ως αγωνιστες υποδοχεα alx
CY1122496T1 (el) Παραγωγα αιμινης με αντιβακτηριακη και αντιιικη δραστικοτητα
CY1117210T1 (el) Παραγωγα 2-οξο-1-ιμιδαζολιδινυλ ιμιδαζοθειαδιαζολης
TR201901977T4 (tr) Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri.
CY1120101T1 (el) Παραγωγο πυριδονης και φαρμακο που το περιεχει
TH158992A (th) อนุพันธ์เบนซิมิดาโซล-โปรลีน
UA112586C2 (uk) Похідні бензімідазолпроліну